-
2025-522796-28-00
4
Acute Ischemic Stroke
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2025-522818-23-00
5
Small Cell Lung Cancer (SCLC)
-
2025-524623-50-00
9
Solid Tumors
-
2025-525013-23-00
4
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
-
2025-522038-29-00
5
2026-06-16
Locally advanced, unresected (unresectable or medically inoperable or
-
2025-521792-31-01
5
2026-04-07
Homozygous Familial Hypercholesterolemia (HoFH)
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2025-522542-40-00
5
2026-06-19
Acute Ischemic Stroke
-
2025-523461-17-01
5
2026-06-01
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-